The TSR in the P-IL-2 and Palbociclib combination group was 74.08%, with a 1.34-fold increase in tumor suppression and a 1.73-fold reduction in tumor volume compared to the IL-2 and Palbociclib combination group. This evidence concerns the gene IL2 and neoplasm.